- Home
- JAZZ vs ORI Comparison
JAZZ vs ORI Comparison
Compare JAZZ & ORI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JAZZ | ORI |
|---|---|---|
| Founded | 2003 | 1923 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 10.4B |
| IPO Year | 2007 | 1994 |
Fundamental Metrics
Financial Performance| Metric | JAZZ | ORI |
|---|---|---|
| Price | $202.60 | $39.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 2 |
| Target Price | ★ $217.57 | $43.50 |
| AVG Volume (30 Days) | 832.5K | ★ 1.4M |
| Earning Date | 05-05-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 9.47% |
| EPS Growth | N/A | ★ 14.81 |
| EPS | N/A | ★ 3.72 |
| Revenue | $1,618,693,000.00 | ★ $9,136,300,000.00 |
| Revenue This Year | $6.22 | $7.07 |
| Revenue Next Year | $7.68 | $6.86 |
| P/E Ratio | ★ N/A | $10.76 |
| Revenue Growth | N/A | ★ 10.99 |
| 52 Week Low | $105.00 | $35.60 |
| 52 Week High | $207.48 | $46.76 |
Technical Indicators
Market Signals| Indicator | JAZZ | ORI |
|---|---|---|
| Relative Strength Index (RSI) | 58.73 | 39.89 |
| Support Level | $194.77 | $38.75 |
| Resistance Level | $207.48 | $43.46 |
| Average True Range (ATR) | 5.09 | 0.94 |
| MACD | -0.29 | -0.25 |
| Stochastic Oscillator | 60.62 | 3.66 |
Price Performance
Historical ComparisonAbout JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About ORI Old Republic International Corporation
Old Republic International Corp is engaged in the business of insurance underwriting and related services. The company operates in two segments: Specialty Insurance and Title Insurance. The insurance provided by the company includes Automobile Extended Warranty Insurance, Aviation, Commercial Automobile Insurance, Inland Marine, Travel Accident, Workers' Compensation, Financial Indemnity, and others. The company generates the majority of its revenue from Specialty Insurance. The Specialty Insurance provides property and liability insurance principally to commercial clients.